Drugmaker Biogen is pulling the plug on its controversial Alzheimer’s drug Aduhelm, following disappointing gross sales. It had been anticipated to be a blockbuster product.
MARY LOUISE KELLY, HOST:
A drugmaker is pulling the plug on an Alzheimer’s remedy that was as soon as anticipated to be a blockbuster. NPR’s Sydney Lupkin experiences on what occurred and what it might imply for sufferers.
SYDNEY LUPKIN, BYLINE: Aduhelm was presupposed to be a giant deal. That is as a result of the drug cleared sticky clumps of protein referred to as amyloid from the brains of sufferers with Alzheimer’s illness. Of the 2 massive research of Aduhelm submitted to the Meals and Drug Administration, one discovered that the drug delayed the lack of reminiscence and pondering, whereas the opposite discovered no clear profit. A panel of specialists advising the company really useful in opposition to approval, however the company did it anyway in 2021 with a catch. Biogen, the drug’s maker, needed to do extra analysis to substantiate Aduhelm labored and get the research executed by 2030. Now Biogen says it could not discover a accomplice or financing to assist pay for the expensive confirmatory research, so it is chopping its losses and specializing in its different FDA-approved Alzheimer’s drug referred to as Leqembi. Dr. Aaron Kesselheim from Harvard was one in every of three FDA advisers who resigned in protest over the Aduhelm approval.
AARON KESSELHEIM: The truth that within the intervening three-plus years that there was no further information that is come out that prompt something constructive about this drug is an indicator to me that the advisory committee was appropriate in assessing this drug didn’t have good proof and shouldn’t have been accredited.
LUPKIN: Aduhelm by no means took off. Biogen initially set its worth at $56,000 a yr, however demand was so weak the corporate slashed the value in half a couple of months later. Medicare additionally restricted protection for Aduhelm to sufferers who had been in scientific trials. Nonetheless, Biogen’s determination to withdraw Aduhelm was surprising. Heather Snyder from the Alzheimer’s Affiliation says sufferers had been nonetheless being enrolled within the confirmatory research when Biogen made its announcement. However she says there is a silver lining.
HEATHER SNYDER: The approval of Aduhelm was a landmark occasion that actually supplied hope for thus many people which can be or had been dwelling with early Alzheimer’s and their households.
LUPKIN: And different experimental Alzheimer’s medication are transferring ahead within the pipeline. Biogen says sufferers at the moment taking Aduhelm may have entry to it till November 1, however sufferers taking the drug in scientific trials will lose entry Could 1. Biogen had licensed the drug from a Swiss biotech referred to as Neurimmune. Neurimmune says it’ll proceed to work on the drug and goals to hunt approval for a model that’s given by injection as a substitute of infusion.
Sydney Lupkin, NPR Information.
(SOUNDBITE OF MUSIC)
Copyright © 2024 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional data.
NPR transcripts are created on a rush deadline by an NPR contractor. This textual content is probably not in its last type and could also be up to date or revised sooner or later. Accuracy and availability could fluctuate. The authoritative file of NPR’s programming is the audio file.
